The significance of granzyme B expression in patients with angiocentric lymphoma of the head and neck

Gwi Eon Kim, Woo Ick Yang, Sang Wook Lee, Yongbae Kim, Chang-Ok Suh, Joo Heon Yoon, Young Taik Oh, Hyuncheol Chung, Byung Soo Kim

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

BACKGROUND. The objectives of this study were to establish a correlation between granzyme B expression and the clinicopathologic characteristics of patients with angiocentric lymphomas of the head and neck and to determine whether the expression of granzyme B had any influence on the treatment outcomes of such patients. METHODS. Fifty-seven patients with angiocentric lymphoma of the head and neck who were treated between 1987 and 1996 were divided into two groups according to whether their tumors were immunoreactive for granzyme B: the granzyme B negative group (n = 22 patients) and the granzyme B positive group (n = 35 patients). The clinicopathologic features, immunohistochemical findings, patterns of disease failure, and survival data for the granzyme B positive group were compared with those for the granzyme B negative group. RESULTS. Greater than 60% of patients with angiocentric lymphoma of the head and neck were shown to have granzyme B positive tumors. All tumors that expressed granzyme B also consistently coexpressed CD56, indicating that they probably are the neoplastic equivalent of either natural killer (NK) cells or activated cytotoxic T cells. Although there were no significant differences in histopathologic features or expression of CD45RO and polyclonal CD3-ε between the groups, the Epstein-Barr virus genomes were detected more frequently in the granzyme B positive group compared with the granzyme B negative group. Despite a similar rate of complete remission after initial treatment, the locoregional recurrence rate of patients in the granzyme B positive group was much higher compared with patients in the granzyme B negative group. In addition, compared with patients in the granzyme B negative group, patients in the granzyme B positive group also had an increased risk of systemic disease recurrence and a decreased overall survival rate. CONCLUSIONS. The data indicate that the cytotoxic granule-associated protein, granzyme B, may be used as an additional marker for identifying NK/T-cell lymphoma and as a prognostic indicator for risk assessment in patients with angiocentric lymphoma of the head and neck.

Original languageEnglish
Pages (from-to)2343-2352
Number of pages10
JournalCancer
Volume91
Issue number12
DOIs
Publication statusPublished - 2001 Jun 15

Fingerprint

Granzymes
Lymphoma
Neck
Head
Recurrence
Neoplasms
Natural Killer T-Cells
T-Cell Lymphoma

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Kim, Gwi Eon ; Yang, Woo Ick ; Lee, Sang Wook ; Kim, Yongbae ; Suh, Chang-Ok ; Yoon, Joo Heon ; Oh, Young Taik ; Chung, Hyuncheol ; Kim, Byung Soo. / The significance of granzyme B expression in patients with angiocentric lymphoma of the head and neck. In: Cancer. 2001 ; Vol. 91, No. 12. pp. 2343-2352.
@article{a53341ee05d44acd8000c152f93539d2,
title = "The significance of granzyme B expression in patients with angiocentric lymphoma of the head and neck",
abstract = "BACKGROUND. The objectives of this study were to establish a correlation between granzyme B expression and the clinicopathologic characteristics of patients with angiocentric lymphomas of the head and neck and to determine whether the expression of granzyme B had any influence on the treatment outcomes of such patients. METHODS. Fifty-seven patients with angiocentric lymphoma of the head and neck who were treated between 1987 and 1996 were divided into two groups according to whether their tumors were immunoreactive for granzyme B: the granzyme B negative group (n = 22 patients) and the granzyme B positive group (n = 35 patients). The clinicopathologic features, immunohistochemical findings, patterns of disease failure, and survival data for the granzyme B positive group were compared with those for the granzyme B negative group. RESULTS. Greater than 60{\%} of patients with angiocentric lymphoma of the head and neck were shown to have granzyme B positive tumors. All tumors that expressed granzyme B also consistently coexpressed CD56, indicating that they probably are the neoplastic equivalent of either natural killer (NK) cells or activated cytotoxic T cells. Although there were no significant differences in histopathologic features or expression of CD45RO and polyclonal CD3-ε between the groups, the Epstein-Barr virus genomes were detected more frequently in the granzyme B positive group compared with the granzyme B negative group. Despite a similar rate of complete remission after initial treatment, the locoregional recurrence rate of patients in the granzyme B positive group was much higher compared with patients in the granzyme B negative group. In addition, compared with patients in the granzyme B negative group, patients in the granzyme B positive group also had an increased risk of systemic disease recurrence and a decreased overall survival rate. CONCLUSIONS. The data indicate that the cytotoxic granule-associated protein, granzyme B, may be used as an additional marker for identifying NK/T-cell lymphoma and as a prognostic indicator for risk assessment in patients with angiocentric lymphoma of the head and neck.",
author = "Kim, {Gwi Eon} and Yang, {Woo Ick} and Lee, {Sang Wook} and Yongbae Kim and Chang-Ok Suh and Yoon, {Joo Heon} and Oh, {Young Taik} and Hyuncheol Chung and Kim, {Byung Soo}",
year = "2001",
month = "6",
day = "15",
doi = "10.1002/1097-0142(20010615)91:12<2343::AID-CNCR1267>3.0.CO;2-3",
language = "English",
volume = "91",
pages = "2343--2352",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "12",

}

The significance of granzyme B expression in patients with angiocentric lymphoma of the head and neck. / Kim, Gwi Eon; Yang, Woo Ick; Lee, Sang Wook; Kim, Yongbae; Suh, Chang-Ok; Yoon, Joo Heon; Oh, Young Taik; Chung, Hyuncheol; Kim, Byung Soo.

In: Cancer, Vol. 91, No. 12, 15.06.2001, p. 2343-2352.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The significance of granzyme B expression in patients with angiocentric lymphoma of the head and neck

AU - Kim, Gwi Eon

AU - Yang, Woo Ick

AU - Lee, Sang Wook

AU - Kim, Yongbae

AU - Suh, Chang-Ok

AU - Yoon, Joo Heon

AU - Oh, Young Taik

AU - Chung, Hyuncheol

AU - Kim, Byung Soo

PY - 2001/6/15

Y1 - 2001/6/15

N2 - BACKGROUND. The objectives of this study were to establish a correlation between granzyme B expression and the clinicopathologic characteristics of patients with angiocentric lymphomas of the head and neck and to determine whether the expression of granzyme B had any influence on the treatment outcomes of such patients. METHODS. Fifty-seven patients with angiocentric lymphoma of the head and neck who were treated between 1987 and 1996 were divided into two groups according to whether their tumors were immunoreactive for granzyme B: the granzyme B negative group (n = 22 patients) and the granzyme B positive group (n = 35 patients). The clinicopathologic features, immunohistochemical findings, patterns of disease failure, and survival data for the granzyme B positive group were compared with those for the granzyme B negative group. RESULTS. Greater than 60% of patients with angiocentric lymphoma of the head and neck were shown to have granzyme B positive tumors. All tumors that expressed granzyme B also consistently coexpressed CD56, indicating that they probably are the neoplastic equivalent of either natural killer (NK) cells or activated cytotoxic T cells. Although there were no significant differences in histopathologic features or expression of CD45RO and polyclonal CD3-ε between the groups, the Epstein-Barr virus genomes were detected more frequently in the granzyme B positive group compared with the granzyme B negative group. Despite a similar rate of complete remission after initial treatment, the locoregional recurrence rate of patients in the granzyme B positive group was much higher compared with patients in the granzyme B negative group. In addition, compared with patients in the granzyme B negative group, patients in the granzyme B positive group also had an increased risk of systemic disease recurrence and a decreased overall survival rate. CONCLUSIONS. The data indicate that the cytotoxic granule-associated protein, granzyme B, may be used as an additional marker for identifying NK/T-cell lymphoma and as a prognostic indicator for risk assessment in patients with angiocentric lymphoma of the head and neck.

AB - BACKGROUND. The objectives of this study were to establish a correlation between granzyme B expression and the clinicopathologic characteristics of patients with angiocentric lymphomas of the head and neck and to determine whether the expression of granzyme B had any influence on the treatment outcomes of such patients. METHODS. Fifty-seven patients with angiocentric lymphoma of the head and neck who were treated between 1987 and 1996 were divided into two groups according to whether their tumors were immunoreactive for granzyme B: the granzyme B negative group (n = 22 patients) and the granzyme B positive group (n = 35 patients). The clinicopathologic features, immunohistochemical findings, patterns of disease failure, and survival data for the granzyme B positive group were compared with those for the granzyme B negative group. RESULTS. Greater than 60% of patients with angiocentric lymphoma of the head and neck were shown to have granzyme B positive tumors. All tumors that expressed granzyme B also consistently coexpressed CD56, indicating that they probably are the neoplastic equivalent of either natural killer (NK) cells or activated cytotoxic T cells. Although there were no significant differences in histopathologic features or expression of CD45RO and polyclonal CD3-ε between the groups, the Epstein-Barr virus genomes were detected more frequently in the granzyme B positive group compared with the granzyme B negative group. Despite a similar rate of complete remission after initial treatment, the locoregional recurrence rate of patients in the granzyme B positive group was much higher compared with patients in the granzyme B negative group. In addition, compared with patients in the granzyme B negative group, patients in the granzyme B positive group also had an increased risk of systemic disease recurrence and a decreased overall survival rate. CONCLUSIONS. The data indicate that the cytotoxic granule-associated protein, granzyme B, may be used as an additional marker for identifying NK/T-cell lymphoma and as a prognostic indicator for risk assessment in patients with angiocentric lymphoma of the head and neck.

UR - http://www.scopus.com/inward/record.url?scp=0035876193&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035876193&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(20010615)91:12<2343::AID-CNCR1267>3.0.CO;2-3

DO - 10.1002/1097-0142(20010615)91:12<2343::AID-CNCR1267>3.0.CO;2-3

M3 - Article

C2 - 11413524

AN - SCOPUS:0035876193

VL - 91

SP - 2343

EP - 2352

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 12

ER -